Non-Toxic DFL Chelators for Iron Overload and Cell Repair
Non-toxic Iron Chelators Designed to Remove Excess Iron from Inside Cells
Tags: The University of Sydney, Australia, Healthcare & Lifesciences
The University of Sydney has developed a new class of iron chelators, DFL, to address iron overload diseases in patients with conditions like beta-thalassemia and sickle cell disease. These chelators effectively remove iron from both plasma and inside cells, addressing a critical gap in current treatments. With a non-toxic profile comparable to DFO and a longer residence time, DFL chelators promise improved patient adherence, reduced dosing, and better treatment outcomes. Applications include managing transfusion-dependent blood disorders, myelodysplastic syndrome, and acute iron poisoning, particularly in children. Protected by a provisional patent filed in November 2023, this technology offers a safer and more efficient alternative to existing iron chelators.
IP Type or Form Factor: Patent Pending; Material; Platform
TRL: 2 - technology concept and/or application formulated
Industry or Tech Area: Pharmaceutical Engineering; Healthcare Provider
